ZNTL – Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc.ZNTL
$1.29Name : Zentalis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $92,636,840.00
EPSttm : -2.33
Zentalis Pharmaceuticals, Inc.
$1.29
2.38%$0.03Float Short %
8.83
Margin Of Safety %
Put/Call OI Ratio
0.81
EPS Next Q Diff
0.04
EPS Last/This Y
0.08
EPS This/Next Y
-0.07
Price
1.29
Target Price
5.97
Analyst Recom
2.2
Performance Q
-46.03
Relative Volume
0.57
Beta
1.83
Ticker: ZNTL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-19 | ZNTL | 1.78 | 0.60 | 1.00 | 2875 |
| 2025-03-20 | ZNTL | 1.82 | 0.60 | 0.00 | 2877 |
| 2025-03-21 | ZNTL | 1.91 | 0.60 | 0.00 | 2877 |
| 2025-03-24 | ZNTL | 1.97 | 1.25 | 0.00 | 1643 |
| 2025-03-25 | ZNTL | 1.865 | 1.22 | 0.00 | 1660 |
| 2025-03-26 | ZNTL | 1.755 | 1.22 | 0.00 | 1661 |
| 2025-03-27 | ZNTL | 1.79 | 1.16 | 5.00 | 1703 |
| 2025-03-28 | ZNTL | 1.81 | 1.16 | 5.00 | 1703 |
| 2025-03-31 | ZNTL | 1.585 | 1.82 | 0.91 | 2227 |
| 2025-04-01 | ZNTL | 1.38 | 1.78 | 0.63 | 2290 |
| 2025-04-02 | ZNTL | 1.355 | 1.78 | 0.63 | 2290 |
| 2025-04-03 | ZNTL | 1.28 | 1.42 | 13.33 | 2067 |
| 2025-04-04 | ZNTL | 1.165 | 1.42 | 13.33 | 2067 |
| 2025-04-07 | ZNTL | 1.155 | 1.46 | 1.56 | 2108 |
| 2025-04-08 | ZNTL | 1.03 | 1.47 | 1.00 | 2057 |
| 2025-04-09 | ZNTL | 1.18 | 0.81 | 999.99 | 1508 |
| 2025-04-10 | ZNTL | 1.135 | 0.81 | 0.20 | 1510 |
| 2025-04-11 | ZNTL | 1.24 | 0.81 | 0.00 | 1511 |
| 2025-04-14 | ZNTL | 1.22 | 0.81 | 0.00 | 1511 |
| 2025-04-15 | ZNTL | 1.275 | 0.81 | 0.00 | 1511 |
| 2025-04-16 | ZNTL | 1.265 | 0.81 | 0.00 | 1511 |
| 2025-04-17 | ZNTL | 1.3 | 0.81 | 0.00 | 1511 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-19 | ZNTL | 1.79 | 17.9 | - | -2.39 |
| 2025-03-20 | ZNTL | 1.82 | 17.9 | - | -2.39 |
| 2025-03-21 | ZNTL | 1.90 | 17.9 | - | -2.39 |
| 2025-03-24 | ZNTL | 1.98 | 17.9 | - | -2.39 |
| 2025-03-25 | ZNTL | 1.87 | 17.9 | - | -2.39 |
| 2025-03-26 | ZNTL | 1.76 | 17.9 | - | -2.39 |
| 2025-03-27 | ZNTL | 1.78 | 17.9 | - | -2.39 |
| 2025-03-28 | ZNTL | 1.81 | 17.9 | - | -2.39 |
| 2025-03-31 | ZNTL | 1.59 | -542.9 | - | -2.41 |
| 2025-04-01 | ZNTL | 1.39 | -542.9 | - | -2.41 |
| 2025-04-02 | ZNTL | 1.36 | -542.9 | - | -2.41 |
| 2025-04-03 | ZNTL | 1.28 | -542.9 | - | -2.41 |
| 2025-04-04 | ZNTL | 1.16 | -533.5 | - | -2.25 |
| 2025-04-07 | ZNTL | 1.15 | -533.5 | - | -2.25 |
| 2025-04-08 | ZNTL | 1.04 | -533.5 | - | -2.25 |
| 2025-04-09 | ZNTL | 1.17 | -533.5 | - | -2.25 |
| 2025-04-10 | ZNTL | 1.14 | -533.5 | - | -2.25 |
| 2025-04-11 | ZNTL | 1.24 | -533.5 | - | -2.25 |
| 2025-04-14 | ZNTL | 1.22 | -533.5 | - | -2.25 |
| 2025-04-15 | ZNTL | 1.27 | -533.5 | - | -2.25 |
| 2025-04-16 | ZNTL | 1.27 | -533.5 | - | -2.25 |
| 2025-04-17 | ZNTL | 1.29 | -533.5 | - | -2.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-19 | ZNTL | 0.49 | -7.66 | 9.66 |
| 2025-03-20 | ZNTL | 0.49 | -7.66 | 9.66 |
| 2025-03-21 | ZNTL | 0.49 | -7.66 | 9.66 |
| 2025-03-24 | ZNTL | 0.49 | -7.42 | 9.66 |
| 2025-03-25 | ZNTL | 0.49 | -7.42 | 9.66 |
| 2025-03-26 | ZNTL | 0.49 | -7.42 | 9.94 |
| 2025-03-27 | ZNTL | 0.49 | -7.42 | 9.94 |
| 2025-03-28 | ZNTL | 0.49 | -7.42 | 9.94 |
| 2025-03-31 | ZNTL | 0.49 | -7.15 | 9.86 |
| 2025-04-01 | ZNTL | 0.49 | -7.15 | 9.86 |
| 2025-04-02 | ZNTL | 0.49 | -7.15 | 9.86 |
| 2025-04-03 | ZNTL | 0.49 | -7.15 | 9.86 |
| 2025-04-04 | ZNTL | 0.49 | -7.15 | 9.86 |
| 2025-04-07 | ZNTL | 0.50 | -6.63 | 9.86 |
| 2025-04-08 | ZNTL | 0.50 | -6.63 | 9.86 |
| 2025-04-09 | ZNTL | 0.50 | -6.63 | 9.86 |
| 2025-04-10 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-11 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-14 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-15 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-16 | ZNTL | 0.50 | -6.63 | 8.83 |
| 2025-04-17 | ZNTL | 0.50 | -6.63 | 8.83 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.66
Avg. EPS Est. Current Quarter
-0.62
Avg. EPS Est. Next Quarter
-0.62
Insider Transactions
0.5
Institutional Transactions
-6.63
Beta
1.83
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
21
Growth Score
26
Sentiment Score
62
Actual DrawDown %
98.5
Max Drawdown 5-Year %
-98.8
Target Price
5.97
P/E
Forward P/E
PEG
P/S
1.37
P/B
0.27
P/Free Cash Flow
EPS
-2.33
Average EPS Est. Cur. Y
-2.25
EPS Next Y. (Est.)
-2.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-245.96
Relative Volume
0.57
Return on Equity vs Sector %
-68.7
Return on Equity vs Industry %
-55.8
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.21
EBIT Estimation
Zentalis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 166
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.
stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today
news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance
stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market
stock prices ZNTL premarket after hours
ticker ZNTL fair value insiders trading